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The vitamin D receptor (VDR) is a ligand-dependent
transcription factor that heterodimerizes with retinoid
X receptor (RXR) and interacts with the basal transcrip-
tion machinery and transcriptional cofactors to regu-
late target gene activity. The p160 coactivator GRIP1
and the distinct coregulator Ski-interacting protein
(SKIP)/NCoA-62 synergistically enhance ligand-depend-
ent VDR transcriptional activity. Both coregulators
bind directly to and form a ternary complex with VDR,
with GRIP1 contacting the activation function-2 (AF-2)
domain and SKIP/NCoA-62 interacting through an AF-2
independent interface. It was previously reported that
SKIP/NCoA-62 interaction with VDR was independent of
the heterodimerization interface (specifically, helices
H10/H11). In contrast, the present study defines specific
residues within a conserved and surface-exposed region
of VDR helix H10 that are required for interaction with
SKIP/NCoA-62 and for full ligand-dependent transacti-
vation activity. SKIP/NCoA-62, the basal transcription
factor TFIIB, and RXR all interacted with VDR helix H10
mutants at reduced levels compared with wild type in
the absence of ligand and exhibited different degrees of
increased interaction upon ligand addition. Thus, SKIP/
NCoA-62 interacts with VDR at a highly conserved re-
gion not previously associated with coregulator binding
to regulate transactivation by a molecular mechanism
distinct from that of p160 coactivators.
The vitamin D receptor (VDR)1 is a ligand-dependent tran-
scription factor important in the regulation of calcium homeo-
stasis, development, cell growth, and differentiation. VDR be-
longs to the nuclear receptor superfamily, members of which
share a common modular structure including a highly con-
served DNA binding domain (DBD) and a conserved ligand
binding domain (LBD). The LBD has a predominantly -helical
structure with an activation function-2 (AF-2) domain in the
COOH-terminal helix (H12). The LBD is the main site of VDR
interaction with its heterodimer partner retinoid X receptor
(RXR) and basal transcription factors, and the AF-2 domain in
combination with the hydrophobic cleft forms an interaction
surface for transcriptional corepressors and coactivators (1, 2).
In the absence of its ligand 1,25-dihydroxyvitamin D3
(1,25(OH)2D3), VDR transcriptional activity is low due to in-
teraction with corepressors such as N-CoR and SMRT and
potentially through sequestration of the basal transcription
factor TFIIB. Addition of 1,25(OH)2D3 causes dissociation of
VDR-corepressor and VDR-TFIIB complexes, thereby relieving
repression (3–5). VDR ligand-dependent activation is facili-
tated by recruitment of at least one coactivator protein with
intrinsic histone acetyl transferase activity, such as p160 coac-
tivators. Recruitment of multiprotein cointegrator complexes
including CBP/p300, p/CAF, and DRIP provide further regula-
tion, coordinating interactions of the receptor with other pro-
teins including basal transcription factors, RNA polymerase II,
and the p160 coactivators (6).
The novel coregulator Ski-interacting protein (SKIP)/NCoA-
62, which is structurally distinct from the p160 coactivators,
was isolated through its interactions with both the Ski onco-
protein and VDR (7, 8). It also interacts with other nuclear
proteins including the repressor CBF-1 and the HPV-16 E7
oncoprotein, can bind coregulators such as SMRT, Sin3A,
HDAC2, and SRC-1, and interacts with Smad proteins to aug-
ment transforming growth factor--dependent transactivation
(7–12). SKIP/NCoA-62 functions in cell fate determination,
alternatively facilitating gene repression by tethering CBF-1 to
the corepressor SMRT and gene activation by tethering CBF-1
to the activator NotchIC (10). Such mutually exclusive inter-
actions with coactivators and corepressors suggest that SKIP/
NCoA-62 may facilitate coregulator switching.
SKIP/NCoA-62 augments transactivation by the vitamin D,
retinoic acid, estrogen, and glucocorticoid receptors (7), selec-
tively binding the VDR:RXR heterodimer in a ligand-enhanced
manner (13). SKIP/NCoA-62 forms a ternary complex and acts
synergistically with the p160 coactivator GRIP1 to augment
VDR transactivation (13). Consistent with such complex for-
mation, p160 coactivators contact VDR through the AF-2 do-
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main, whereas SKIP/NCoA-62 interactions with VDR are AF-
2-independent. SKIP/NCoA-62 reportedly contacts helix H1 of
the VDR LBD (residues 116–164 of human VDR) and the helix
H10/H11 region (residues 373–403) but not helix H12 (7). It
was subsequently shown, however, that SKIP/NCoA-62 could
bind to the VDR:RXR heterodimer, leading to the conclusion
that the heterodimerization interface (including helix H10/
H11) could be excluded as a SKIP/NCoA-62 interaction surface
(13).
In the present study, we further investigated structural as-
pects of VDR-SKIP/NCoA-62 interaction to determine how
structure may mediate SKIP/NCoA-62 function. An interaction
site was mapped to helix H10 of mouse VDR by mutational
analysis. Alteration of structurally exposed amino acids of this
helix markedly reduced 1,25(OH)2D3-independent interactions
with SKIP/NCoA-62 but not ligand-dependent interactions
with the p160 coactivators GRIP1 and RAC3. These same VDR
residues were required for interaction with RXR regardless of
ligand status and for ligand-independent interaction with
TFIIB. The results indicate that a transcriptional coactivator, a
basal transcription factor, and the VDR heterodimerization
partner each interact with VDR at the same helix H10 inter-
face, with varying ligand sensitivities. As SKIP/NCoA-62 inter-
acts with both unliganded and liganded VDR, the data also
suggest that it may modulate the ligand-regulated occupancy of
this VDR surface by TFIIB and RXR.
EXPERIMENTAL PROCEDURES
Plasmids and Mutagenesis—Mouse VDR (mVDR) was amplified
from full-length cDNA (T. Kawada, Kyoto University) using wild type or
mutant primers containing stop codons (for truncation mutants 397,
389, and 380) or point mutations and cloned into pSG5 (Stratagene)
and pAS2–1 (Clontech). Mutant 389 was further mutated to create
389Q380E, 389D384K, 389R386E, and 389AX3, the last being a
triple point mutant with coordinate Q380A, D384A, and R386A
changes. Full-length wild type cDNA was similarly mutated to produce
mutant AX3. Constructs pACTIISKIP (amino acids 145–536) (12), pAC-
TIITFIIB (14), pACTII-RXR, pGAD424-GRIP1 (nucleotides 204–
4878), pGAD10-RAC3 (nucleotides 1289–3698), pSG5GRIP1, and
pSG5RAC3 (15) have been described.
Molecular Modeling—A model of the mouse VDR LBD was built
using the 1.8-Å resolution crystal structure of the liganded human VDR
LBD as a template (Protein Data Bank accession code 1DB1; Ref. 2).
Initial CLUSTALW (16) alignments were performed using the LBD
sequences of hRAR, -, and -; hRXR, -, and -; hTR and -;
hPPAR, -, and -; and hVDR, rVDR, and mVDR, with subsequent
analyses performed using hRAR, hVDR, rVDR, and mVDR sequences.
Modeling was performed using InsightII and Homology version 98
software (Molecular Simulations Inc., San Diego, CA). The model of the
LBD was built from residue 124 and required no insertions or deletions.
Side chain rotamer positions were searched by retaining identical res-
idues in their original positions, and automatically placing others based
on their size and flexibility, placing large hydrophobic residues before
small side chains. Species-related changes in the structure of mVDR
due to the excised insertion domain or sequence differences, which are
away from the ligand binding and interaction sites, are anticipated to
be minor.
Yeast Two-hybrid Assays—pAS2–1mVDRWT or mutant constructs
were transformed into SFY526 cells and tryptophan-selected. pACTI-
ISKIP (amino acids 145–536), pACTIITFIIB, pACTII-RXR GAD424-
GRIP1, and pGAD10-RAC3 were individually transformed into Y187
cells and leucine-selected. Haploid SFY526 and Y187 strains were
mated and diploid strains selected with tryptophan and leucine. Six
independent colonies from each diploid strain were tested in ligand
assays as described previously (14). Cell lysate protein content was
determined (Bio-Rad), and -galactosidase activity was assayed by
chemiluminescence (Tropix).
Immunoblot Analysis—Lysates were prepared from diploid yeast
strains (14) and mammalian cells (17). Equal amounts of protein were
resolved by SDS-PAGE (10%), blotted, and probed with 9A7 antibody
(Affinity Bioreagents Inc.) to detect VDR and anti-HA tag antibody
(Roche Molecular Biochemicals) to detect HA-SKIP.
GST Binding Assays—GST-SKIP (12), GST-TFIIB (18), GST-
mRXR (19), and GST-O (Amersham Biosciences) fusion proteins were
expressed in Escherichia coli BL21, purified, and coupled to glutathi-
one-Sepharose as described (Amersham Biosciences). Whole cell lysates
containing VDR wild type and mutant proteins were prepared (20) from
COS-1 cells transfected with pSG5 mVDR expression constructs. GST
binding reactions were performed (14) in the presence of 107 M
1,25(OH)2D3 or vehicle. Bound proteins were eluted, electrophoresed,
and immunoblotted with 9A7 antibody.
Coimmunoprecipitation Assays—pSG5WT and mutant VDR con-
structs, pSG5GRIP1 and pSG5RAC3, were transcribed and translated
in vitro using the TNTTM T7 quick coupled system (Promega). [35S]Me-
thionine was incorporated into GRIP1 and RAC3 polypeptide products.
Binding reactions were performed (21) in the presence of 107 M
1,25(OH)2D3 or vehicle. Complexes were immunoprecipitated with 9A7
antibody and anti-rat IgG-Sepharose 4B beads (Zymed Laboratories
Inc.. Bound complexes were eluted, separated by SDS-PAGE (10%), and
dried gels were autoradiographed.
Cell Culture and Transfections—COS-1 cells were transfected for 6 h
using FuGENETM (Roche Molecular Biochemicals) with 30 ng of
pSG5WT or mutant, 450 ng of pGL3–24-hydroxylase-LUC reporter (3),
and 60 ng of pRSVgal control plasmid. Cells were then treated with
vehicle or 1010, 108, or 106 M 1,25(OH)2D3 for 16 h, harvested, and
assayed for luciferase (Promega) and -galactosidase activities. Lucif-
erase activity was corrected for transfection efficiency using -galacto-
sidase results.
RESULTS
VDR Helix H10 Residues Form SKIP/NCoA-62 Interaction
Interface—SKIP/NCoA-62 has been reported to interact with
human VDR through residues 373–403 in the helix H10/H11
region, excluding the AF-2 domain (7). In the present study a
series of truncation mutants in this region of the highly con-
served mouse VDR were generated, deleting helices H12
(397), H11, and H12 (389) or part of H10 plus H11 and H12
(380), the last mutation removing the highly conserved ninth
heptad repeat (1) (Fig. 1, A and B). Wild type VDR interacted
with SKIP/NCoA-62 in the absence and presence of ligand in
yeast two-hybrid assays, as did the 397 and 389 mutants
(Fig. 2A). The 380 mutant failed to interact with SKIP/NCoA-
62, implicating mVDR residues 380–389 in this interaction.
A model of the mVDR LBD was built based on the highly
homologous (89% identity) human VDR LBD (2). Residues
380–389 lie on helix H10 at the receptor surface (Fig. 1C),
forming part of an exposed ridge, with the polar or charged side
chains of the conserved residues Gln-380, Asp-384, and Arg-
386 particularly prominent midway along the helix. The gua-
nidinium group of Arg-386 appears in a highly conserved
bridge with Asp-337, stacked on Arg-338, making the aliphatic
component of the side chain more prominent in the model
structure. Based on the accessibility of the side chains to the
exterior, flexibility in Gln-380, Asp-384, and Arg-386 is antic-
ipated. To investigate their potential involvement in SKIP/
NCoA-62 interaction, these three residues were individually
mutated to retain similar bulk but altered charge in the context
of 389 (Q380E, D384K, or R386E; Fig. 1A). Each point muta-
tion diminished VDR interaction with SKIP/NCoA-62 by 60–
80% compared with wild type and 389 controls (Fig. 2B).
Similarly, coordinate mutation of these residues to alanine in
the 389 context (389AX3 mutant) decreased this interaction
by 80%. Interaction of the full-length VDR AX3 mutant was
limited to 25% of wild type in the absence of ligand, but
approached wild type levels with 1,25(OH)2D3 (Fig. 2C). Wild
type VDR interaction with GST-SKIP in vitro was also compa-
rable both with and without ligand (Fig. 2D). Mutant AX3
bound less strongly, although without the ligand-induced in-
crease in SKIP/NCoA-62 interaction seen in yeast.
VDR Helix H10 Not Required for p160 Coactivator Interac-
tion—In contrast to SKIP/NCoA-62, interactions of the p160
coactivators GRIP1 and RAC3 with wild type and AX3 mutant
VDR were entirely ligand-dependent (Fig. 3A). Interestingly,
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p160 coactivator interactions with AX3 were elevated by50%,
suggesting that residues Gln-380, Asp-384, and Arg-386 may
negatively affect access of p160 coactivators to the hydrophobic
cleft on the LBD. Neither 389 nor 389AX3 interacted with
GRIP1 or RAC3, consistent with the AF-2 deletion. In vitro
interactions between the p160 coactivators and VDR mutants
were consistent with the yeast data (Fig. 3B). Thus, VDR helix
H10 is important for interaction with SKIP/NCoA-62 but not
p160 coactivators.
VDR Helix H10 Mutations Inhibit Transactivation Func-
tion—Effects of these helix H10 mutations on VDR function
were assessed by transient transfection. Transactivation by
either wild type or AX3 mutant VDR was 1,25(OH)2D3 dose-
responsive, but AX3 activity was limited to about 40% of wild
type at the highest dose tested, despite comparable VDR pro-
tein levels (Fig. 3C). Thus, the integrity of helix H10 residues
Gln-380, Asp-384, and Arg-386 is necessary for efficient VDR
transactivation.
Other Interactions at Helix H10 Interface—In addition to
SKIP/NCoA-62, TFIIB and RXR also interact with this region
of VDR (5, 22–24), so their interactions with the helix H10
mutants were investigated. Two-hybrid interaction of wild type
FIG. 1. VDR COOH-terminal mutant structure and LBD modeling. A, alignment of human and mouse VDR COOH-terminal amino acid
sequences. -Helical regions are indicated by overlines. Truncation points of mutants 397, 389, and 380 are indicated by horizontal arrows.
Point mutations indicated by unfilled vertical arrows; coordinate mutation of residues 380, 384, and 386 in AX3 mutant is indicated by filled
vertical arrows enclosed in dashed box. B, alignment of helix H10 amino acid residues. Residues analogous to mVDR Gln-380, Asp-384, and Arg-386
are boxed. Residues within the ninth heptad repeat are indicated. C, ribbon diagrams of mVDR LBD model. Left panel shows the prominent helix
H10 residues Gln-380, Asp-384, and Arg-386 in profile, with the helix oriented so that the right side represents the most exposed region. The right
panel is rotated 90 degrees clockwise. The figure was prepared with MOLSCRIPT (31).
FIG. 2. SKIP/NCoA-62 interactions with VDR COOH-terminal
mutants. Yeast two-hybrid assay of strains expressing HA-tagged
SKIP (amino acids 145–536), with mVDR wild type and mutants: A,
397, 389, or 380; B, 389, 389Q380E, 389D384K, 389R386E,
and 389AX3; C, AX3 and treated with vehicle (open bars) or 108 M
1,25(OH)2D3 (solid bars). Western blots confirm VDR and HA-SKIP
expression. D, in vitro binding assay of mVDR wild type or AX3 with
GST-SKIP or GST-0, with or without 107 M 1,25(OH)2D3. Input was
10% of VDR added. Electrophoresed products were probed for VDR
protein levels.
FIG. 3. VDR H10 mutant interactions with p160 coactivators
and transactivation function. A, yeast two-hybrid interactions of
mVDR wild type, AX3, 389, or 389AX3 mutant, and GRIP1 or RAC3.
Treatment with vehicle (open bars) or 108 M 1,25(OH)2D3 (solid bars).
B, coimmunoprecipitations of in vitro translated VDR and GRIP1 or
RAC3 (35S-labeled). Complexes were precipitated using the VDR-spe-
cific 9A7 antibody. Input was 10% of coactivator added; “no VDR” was
coactivator immunoprecipitated without VDR. C, AX3 mutant transac-
tivation function. Wild type or AX3 mutant VDR was transfected into
COS-1 cells with the 24-hydroxylase promoter-luciferase reporter and
treated with increasing concentrations of 1,25(OH)2D3. VDR expression
in transfected lysates was confirmed by immunoblotting.
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VDR with TFIIB was inhibited by 30% upon addition of
1,25(OH)2D3 (Fig. 4A), consistent with a previous report that
VDR-TFIIB contact is inhibited by ligand (5). Interaction of
AX3 with TFIIB in the absence of ligand was 25% of wild
type, but reinstated to wild type level with 1,25(OH)2D3. Inter-
action of 389 with TFIIB was independent of ligand and at
least as strong as wild type. In contrast, interaction of
389AX3 with TFIIB was notably diminished, with and with-
out ligand. Binding of wild type VDR with GST-TFIIB in vitro
was also inhibited by ligand (Fig. 4B). AX3-TFIIB interaction
was weaker than wildtype, but with no ligand-induced increase
as in yeast.
Unliganded wild type VDR interacted with RXR and was
augmented 3-fold by 1,25(OH)2D3 (Fig. 4A). In contrast, un-
liganded AX3 did not interact with RXR, and 1,25(OH)2D3
induced interaction to only 30% of wild type level. Mutant
389-RXR interaction was comparable with wild type VDR
without ligand and was unaffected by ligand treatment, as
389 does not bind 1,25(OH)2D3 (data not shown). Coordinate
alanine mutation completely abrogated 389AX3 interactions
with RXR. In vitro binding data of VDR with RXR correlated
with yeast results, as binding of wild type and AX3 to GST-RXR
increased with ligand, with AX3 binding lower than wild type
(Fig. 4B). Together these data indicate that mVDR helix H10
residues 380, 384, and 386 are important for interactions with
TFIIB and RXR as well as SKIP/NCoA-62. Ligand effects on
these interactions of wild type VDR differed, as VDR-SKIP/
NCoA-62 interactions were ligand-independent, whereas VDR-
TFIIB interactions were inhibited by 1,25(OH)2D3 and those
for VDR:RXR were augmented.
DISCUSSION
SKIP/NCoA-62 is unique among nuclear receptor coregula-
tors in that its interactions with VDR appear to be independent
of the hydrophobic cleft/AF-2 domain interface, relying instead
on an undefined LBD site. In this study we defined the struc-
tural nature of this interaction interface and highlighted its
importance in VDR function and protein interactions. COOH-
terminal mutagenesis of mVDR identified three helix H10 res-
idues, Gln-380, Asp-384, and Arg-386, required for full inter-
action with SKIP/NCoA-62, but not with p160 coactivators.
Distinct differences in ligand-responsive interactions between
helix H10 mutants and SKIP/NCoA-62, TFIIB, or RXR were
observed. Helix H10 mutation also attenuated VDR transacti-
vation function, presumably as a result of disrupted interac-
tions not only with TFIIB and RXR, but also with SKIP/NCoA-
62. Wild type VDR interacted with SKIP/NCoA-62 in both the
absence and presence of 1,25(OH)2D3, whereas its interaction
with TFIIB was partially inhibited and with RXR was aug-
mented by 1,25(OH)2D3, consistent with earlier reports (5, 7,
13).
Mutagenesis of mVDR H10 residues Gln-380, Asp-384, and
Arg-386 markedly reduced ligand-independent interactions
with SKIP/NCoA-62 and TFIIB and completely abrogated RXR
interaction. Ligand treatment restored interactions with TFIIB
fully, and with SKIP/NCoA-62 and RXR partially. Thus, in the
absence of ligand the bulky side chains of these helix H10
residues appear to present a prominent interaction site, as
their removal in AX3 attenuated protein-protein interactions.
The reinstatement of interactions upon ligand treatment may
result from a conformational change that brings additional
interacting regions into play. This proposal is consistent with a
requirement for hVDR helix H1 residues 116–165 for SKIP/
NCoA-62 interaction (7), and for sites in the DNA binding and
ligand binding domains of VDR for TFIIB and RXR interactions
(22–26).
Interaction of SKIP/NCoA-62 with the VDR helix H10 inter-
face would be compatible with concurrent binding of GRIP-1 to
the AF-2-dependent hydrophobic cleft and thus consistent with
ternary complex formation in the presence of ligand (13). SKIP/
NCoA-62 interaction with helix H10 of unliganded VDR would
also be compatible with formation of a repressive ternary com-
plex in the absence of ligand, as SKIP/NCoA-62 and unliganded
VDR both interact with NCoR and SMRT (3, 4, 10). Further-
more, by analogy with its tethering function in the alternate
recruitment of corepressors and coactivators in Notch pathway
regulation (10), SKIP/NCoA-62 may perform a similar function
in VDR signaling, i.e. coordinating interactions with unligan-
ded VDR to mediate transcriptional repression and with ligan-
ded receptor to mediate a switch to transcriptional activation.
This proposal is supported by the finding that SKIP/NCoA-62
can augment or repress VDR transactivation in a cell-specific
manner (27).
Modulation of VDR protein interactions by SKIP/NCoA-62
may also help regulate its interactions with TFIIB and RXR. It
has been proposed that ligand-induced disruption of VDR-
TFIIB interactions releases TFIIB for incorporation into the
transcription complex (5). SKIP/NCoA-62 may regulate this
transition through dynamic helix H10 interactions, as it can
interact directly with TFIIB (data not shown) in addition to
both unliganded and liganded VDR. Similarly, SKIP/NCoA-62
may facilitate RXR interaction with VDR when ligand is pres-
ent, consistent with formation of a ternary complex between
SKIP/NCoA-62 and the liganded VDR:RXR heterodimer (13).
Such a modulator role for SKIP/NCoA-62 may also be impor-
tant for nuclear receptors other than VDR. Residues Gln-380,
Asp-384, and Arg-386 are in the ninth heptad repeat region,
which is highly conserved among the nuclear receptors. Con-
sistent with this conservation, TFIIB interacts with RXR and
TR (14, 28), and RXR contacts PPAR and RAR (29, 30)
through heptad 9 residues analogous to mVDR Gln-380, Asp-
384, and Arg-386. By extension, therefore, SKIP/NCoA-62 may
also interact with nuclear receptors other than VDR via the
helix H10 interface.
FIG. 4. VDR H10 mutant interactions with TFIIB and RXR. A,
yeast two-hybrid interactions of mVDR wild type, AX3, 389, or
389AX3 mutant with TFIIB or RXR, with vehicle (open bars) or 108
M 1,25(OH)2D3 (solid bars) treatment. B, in vitro binding of mVDR wild
type or AX3 with GST-TFIIB, GST-RXR, or GST-0, with or without 107
M 1,25(OH)2D3. Input was 10% of VDR used in binding reactions.
Electrophoresed products were probed for VDR protein levels.
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In summary we have found that the coregulator SKIP/
NCoA-62 interacts with VDR via a helix H10 interface that is
functionally and physically distinct from the region bound by
the AF-2-dependent p160 coactivators. This previously uniden-
tified coactivator interaction surface is required for full VDR
transactivation activity and comprises conserved residues from
helix H10 that are also involved in TFIIB interaction and
heterodimerization with RXR. Moreover, the interactions of
SKIP/NCoA-62, TFIIB, and RXR with the VDR helix H10 in-
terface are dynamic, with varying responses to ligand. This
study elucidates the structural basis of VDR-SKIP/NCoA-62
interactions and suggests that SKIP/NCoA-62 may regulate
the exchange between TFIIB and RXR at the VDR helix H10
interface. Furthermore, it highlights the novel role of SKIP/
NCoA-62 in VDR transcriptional regulation, a role that may
also extend to other nuclear receptors.
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